Lomond Therapeutics Completes Reverse Merger with Venetian-1 and Raises $44M
November 4, 2024
Lomond Therapeutics completed a reverse merger with Venetian-1 Acquisition Corp., which changed its name to Lomond Therapeutics Holdings, Inc., and closed a $44 million private placement led by existing and new investors. The financing included participation from OrbiMed, Torrey Pines Investment, Deerfield Management, American Financial Group and Heights Capital and will fund advancement of Lomond’s clinical-stage oncology programs (lomonitinib, lonitoclax and a menin inhibitor).
- Buyers
- Venetian-1 Acquisition Corp., Montrose Capital, OrbiMed, Torrey Pines Investment, Deerfield Management Company, American Financial Group, Heights Capital
- Targets
- Lomond Therapeutics, Inc.
- Industry
- Biotechnology
- Location
- Delaware, United States
- Transaction Type
- Buyout
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.